MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Minimal Residual Disease Testing Market Size and Trends

The minimal residual disease testing market is estimated to be valued at USD 2.31 Bn in 2024 and is expected to reach USD 4.97 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 11.6% from 2024 to 2031.

To learn more about this report, request sample copy

The minimal residual disease testing market is expected to witness significant growth over the forecast period. This can be primarily attributed to rising cancer prevalence worldwide coupled with increasing adoption of minimal residual disease testing in healthcare facilities for accurate prognosis prediction. MRD technologies enable detection of residual tumor cells which helps determine appropriate treatment approach and chance of relapse. With benefits such as real-time disease monitoring and treatment optimization, the demand for MRD tests is expected to surge substantially in the coming years. Additionally, ongoing efforts by market players to develop highly sensitive technologies will further aid the market expansion through the forecast period.

Rising Prevalence of Blood Cancer and Improved Treatment Outcomes

The increasing incidence and prevalence of various types of hematological malignancies including leukemia, lymphoma, and multiple myeloma across the world has been a major factor fueling the demand for minimal residual disease testing. According to key opinion leaders, the early and accurate detection of residual cancer cells after initial treatment is critical in blood cancers in order to assess treatment response and make adjustments to therapy if needed. MRD testing allows physicians to closely monitor patients and customize their treatment approach. For instance, in August 2022, according to data published by Blood Cancer UK Research, it was stated that blood cancer is the fifth most common cancer in the U.K., with over 41,000 people being diagnosed with it every year. With advancements in treatment options such as targeted therapies, immunotherapy, and stem cell transplantation, more patients are achieving remission and long-term survival. However, the risk of relapse persists if residual cancer cells remain present even at low levels after primary treatment. MRD testing helps identify such residual disease that may not be detected by conventional imaging and ensures patients receive timely and appropriate intervention such as additional chemotherapy cycles or stem cell transplant. This is expected to improve long term outcomes. The ability of MRD to predict relapse and guide treatment strategies non-invasively without the need for invasive biopsies provides a significant advantage. With growing success rates of initial treatments, monitoring of MRD will become an important tool helping clinicians effectively manage blood cancer patients over the long term.

There is a growing trend in the oncology field towards more personalized and precision medicine based on a patient’s specific disease characteristics and risk factors. Advanced MRD technologies allow the quantitative assessment of the tumor burden right down to a single cancer cell. Key opinion leaders note that MRD status is already used to personalize post-remission therapy decisions in some blood cancer types. For example, in acute myeloid leukemia, an MRD negative status may allow stopping further treatment whereas MRD positivity could warrant a stem cell transplant. Researchers are also exploring use of MRD for predicting survival outcomes and tailoring surveillance schedules accordingly. As clinical studies establish MRD as a reliable biomarker, its use for personalized risk stratification and subsequent personalization of treatment regimens is expected to increase tremendously. This drives the need for the wider adoption of sensitive and standardized MRD testing methods across the continuum of care.